Johnson & Johnson
Johnson & Johnson Corrects Q1 2024 Sales Guidance Midpoint
Summary
Johnson & Johnson amended its Form 8-K to correct a typographical error in the April 2024 guidance midpoint for operational sales from $88.0 to $88.9 billion. The company reported a 2.3% increase in overall reported sales for Q1 2024 to $21.4 billion, with operational growth of 3.9% and adjusted operational growth of 4.0%. Adjusted EPS increased to $2.71, up 12.4% year-over-year. The company also increased the midpoint for full-year 2024 operational sales and adjusted operational EPS guidance. Johnson & Johnson provided updates on regulatory approvals and product launches across its Innovative Medicine and MedTech segments.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement